Stock Groups

Britain approves Merck’s oral COVID-19 pill in world first -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO: An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021.

(Reuters) – Britain approved Thursday a COVID-19 oral antiviral pill, jointly developed by Ridgeback Biotherapeutics and Merck. This is a significant step in the global fight against pandemics.

The Medicines and Healthcare products Regulatory Agency, (MHRA), recommended that molnupiravir be taken as soon as possible after a positive COVID-19 testing and five days following the onset symptoms.

In due course, the NHS and the government will confirm that COVID-19 will be available for patients.

Merck stated separately that 10,000,000 courses were expected by the end-of-this year. At least 20 million are planned to be made in 2022.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media does not accept any liability for trade losses that you may incur due to the use of these data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from relying on data including charts, buy/sell signals, and quotes. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.



[ad_2]